Viatris offers a 10.51% free-cash-flow yield and meaningful pipeline optionality as portfolio simplification creates a potentially undervalued stabilizing value play.
Overview
Viatris Inc. (VTRS), formed through the November 2020 merger of Mylan and Pfizer’s Upjohn business, is a global medicines company serving approximately 1 billion patients annually across more than 165 countries. Its diversified Brands and Generics portfolio spans cardiovascular, central nervous system, specialty, injectable, transdermal, and complex generic products. **The company is at a strategic inflection point**, having completed major divestitures that simplify the portfolio, reduce lower-margin manufacturing exposure, and support debt reduction. Q1 2026 revenue rose 8% reported and 3% operationally to $3.517 billion, while adjusted EPS increased 18% to $0.59 and exceeded consensus by 13.46%. Management reaffirmed 2026 guidance of $14.450 billion to $14.950 billion revenue, $4.150 billion to $4.450 billion adjusted EBITDA, $2.33 to $2.47 adjusted EPS, and $1.950 billion to $2.350 billion adjusted FCF. At approximately $17.56, the shares trade at roughly 7.18x forward earnings and a 10.51% free-cash-flow yield. The principal catalysts are cost savings, Indore remediation, pipeline decisions, and potential Selatogrel and Cenerimod launches. The report’s probability-weighted five-year value is $27.28, implying substantial upside, although generic pricing, leverage, and execution risks justify a value-oriented rather than high-growth characterization.